Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19118012
Cho YY, et al. (2009) Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation. Cancer Res 69, 272-81 19118012
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
PD98059 EGF inhibit treatment-induced increase
SP600125 EGF inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
PD98059 EGF inhibit treatment-induced increase
SP600125 EGF inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
PD98059 EGF inhibit treatment-induced increase
SP600125 EGF inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
PD98059 EGF inhibit treatment-induced increase
SP600125 EGF inhibit treatment-induced increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF no change compared to control
SP600125 EGF no change compared to control

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF no change compared to control
SP600125 EGF no change compared to control

S63-p - Jun (human)
Modsite: kNsDLLtsPDVGLLk SwissProt Entrez-Gene
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p, Jun (cow): S63‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phosphoamino acid analysis, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), JB6 CI41 (epidermal), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE JNK1 (human)
KINASE CDK3 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK3 (human) phospho-antibody, transfection of dominant-negative enzyme, co-immunoprecipitation, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EKI-785 EGF inhibit treatment-induced increase
PD98059 EGF no effect upon treatment-induced increase
SP600125 EGF no effect upon treatment-induced increase
siRNA EGF CDK3 (human) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  activity, induced
Effect of modification (process):  cell growth, altered, transcription, altered

S73-p - Jun (human)
Modsite: VGLLkLAsPELERLI SwissProt Entrez-Gene
Orthologous residues
Jun (human): S73‑p, Jun (mouse): S73‑p, Jun (rat): S73‑p, Jun (cow): S73‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phosphoamino acid analysis, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), JB6 CI41 (epidermal), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE JNK1 (human)
KINASE CDK3 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK3 (human) phospho-antibody, transfection of dominant-negative enzyme, co-immunoprecipitation, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EKI-785 EGF inhibit treatment-induced increase
PD98059 EGF no effect upon treatment-induced increase
SP600125 EGF no effect upon treatment-induced increase
siRNA EGF CDK3 (human) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  activity, induced
Effect of modification (process):  cell growth, altered, transcription, altered